» Articles » PMID: 24276032

HbSD-Punjab: Clinical and Hematological Profile of a Rare Hemoglobinopathy

Overview
Specialty Pediatrics
Date 2013 Nov 27
PMID 24276032
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Compound heterozygous HbSD-Punjab is an uncommon hemoglobinopathy encountered in Indians. Limited literature is available about its clinical course. The aim of this study was to describe the clinical and hematological profile of HbSD-Punjab patients from North India.

Materials And Methods: HbSD-Punjab patients diagnosed in the hematology clinics between year 2000 and 2010 were reviewed retrospectively. The diagnosis was established using high-performance liquid chromatography, molecular analysis, and family screening. Clinical details, laboratory parameters, and therapy details were recorded from case records.

Results: Ten patients were identified. Median age at onset of symptoms was 3.5 years (interquartile range [IQR], 1.9 to 7.2). Clinical presentation included: anemia in 3, painful vaso-occlusive crisis in 2, acute chest syndrome in 2, and 3 were diagnosed incidentally. All had moderate to severe anemia (mean hemoglobin [Hb]: 6.8 ± 1.2 g/dL). Eight required red cell transfusions (median: 3 [IQR, 2 to 8]). On high-performance liquid chromatography, median HbF, HbD, and HbS were 12.1% (IQR, 9 to 18.3), 39.7% (IQR, 35 to 42), and 38.5% (IQR, 29 to 43). Five patients received hydroxyurea (HDU), median dose: 20 mg/kg/d (IQR, 18 to 23) with median duration of 7 months (IQR; 6, 45). Increment in Hb and reduction in painful crisis was observed in response to HDU.

Conclusions: HbSD-Punjab has a heterogeneous clinical presentation. Anemia and sickle crises are quite common. HDU may be considered for those presenting with severe phenotype.

Citing Articles

Hemoglobin Variants as Targets for Stabilizing Drugs.

Zoldakova M, Novotny M, Khakurel K, Zoldak G Molecules. 2025; 30(2).

PMID: 39860253 PMC: 11767434. DOI: 10.3390/molecules30020385.


A systematic review on hydroxyurea therapy for sickle cell disease in India.

Pandey A, Kaur H, Borah S, Khargekar N, Karra V, Adhikari T Indian J Med Res. 2023; 156(2):299-311.

PMID: 36629190 PMC: 10057355. DOI: 10.4103/ijmr.ijmr_3447_21.


Profile of Hemoglobin D (HbD) Disease in Eastern Uttar Pradesh: A Single-Center Experience.

Gupta V, Aggarwal P Cureus. 2022; 14(10):e30782.

PMID: 36337804 PMC: 9621097. DOI: 10.7759/cureus.30782.


Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease.

Darshana T, Rees D, Premawardhena A Orphanet J Rare Dis. 2021; 16(1):148.

PMID: 33757549 PMC: 7989007. DOI: 10.1186/s13023-021-01781-w.


A Case of Hemoglobin Sickle-D Punjab.

Ali W, Jain M, Agarwal S, Kumar A Indian J Hematol Blood Transfus. 2020; 36(1):205-207.

PMID: 32158109 PMC: 7042435. DOI: 10.1007/s12288-019-01179-6.